Clinical Trial Update: A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC) [Phase 2]

View source ↗

Summary

Phase IIa randomized study evaluating radium-223 dichloride with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer; complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Enzalutamide (enzalutamide)
• Radium-223 dichloride (radium-223 dichloride)

Snippet

Sponsor: Bayer | Conditions: Prostatic Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2017-07-02